Detailed Narrative
Kenalog Acquisition Bolsters CHG Portfolio
Piramal Pharma entered an agreement to acquire Kenalog from BMS for an upfront consideration of $35 million, with potential contingent payments of $65 million. The product is a branded commercial injectable with complex manufacturing requirements, which limits competition and supports EBITDA margins comparable to the existing CHG portfolio. Management expects the product to generate annualized revenues between $30 million and $40 million, with the transaction expected to close in approximately three months.
CDMO Recovery Driven by RFP Inflow
The CDMO business reported Q3 revenue of ₹1,166 crores, but management noted a sharp rebound in the US biopharma funding environment during H2 Calendar Year '25. This has translated into a significant increase in RFPs and order inflows since October 2025, particularly at onshore facilities like Grangemouth and Riverview. While the decision cycle for new projects is typically 180 days, the increased proposal volume provides visibility for healthier growth in FY27.
Consumer Healthcare Maintains Strong Momentum
The PCH segment grew by 20% in Q3 FY26, led by 'power brands' like Little’s and Lacto Calamine, which grew at 30%. E-commerce continues to be a standout performer, growing at over 50% and now contributing 26% to total PCH sales. The business has already broken even and is expected to show margin expansion in the coming years as it scales further without requiring external capital infusion.
Regulatory and Operational Headwinds at Digwal
The ramp-up of Sevoflurane supplies from the lower-cost Digwal facility for rest-of-world markets has been slower than anticipated due to regulatory delays. Management expects individual ROW market approvals to come through over the next 12 to 18 months. Despite these delays, Piramal increased its US market share in inhalation anesthesia to 47%, maintaining its leadership position in mature markets.
Strategic Capex and Asset Utilization Targets
The company is investing $90 million to expand sterile injectables and payload linker capabilities at Lexington and Riverview. The Riverview expansion is expected to come online in Q4 FY26, while Lexington is slated for the end of Calendar Year '27. Management aims to improve asset turns from the current level of below 1 to a target of 2.0-2.5 as capacity utilization at overseas sites improves.